Cutting hundreds of products in the US, reallocating commercial resources to the most responsive brands around the world, creating a network of centers of excellence and consolidating production capacity are among the measures included in a wide-ranging reform program that Mylan is undertaking as it prepares to merge midway through next year with Pfizer’s Upjohn off-patent brands unit to form a company that will be called Viatris.
Group president Rajiv Malik said the company’s management and board had developed “an integrated transformation plan for Mylan’s standalone business”...
